Janus kinase (JAK) inhibitors and their potential to compete with Sanofi and Regeneron Pharmaceuticals Inc.'s much-touted Dupixent (dupilumab) to treat atopic dermatitis have taken centre-stage at the European Academy of Dermatology and Venereology meeting in Geneva.
The congress in Switzerland saw yet more strong data presented on Dupixent, which some analysts have predicted could be a mega-blockbuster, helped by its potential as an asthma treatment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?